Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Comparing MRD analysis methods

Hervé Avet-Loiseau • 14 Sep 2019
IMW 2019
Multiple Myeloma
CASSIOPEIA

Hervé Avet-Loiseau, MD, PhD, Cancer Research Center of Toulouse, Toulouse, France, summarizes the comparison of flow-cytometry and next-generation sequencing (NGS) in the IFM Cassiopeia trial. Interview recorded at the International Myeloma Workshop (IMW) 2019, Boston, MA.

More from Hervé Avet-Loiseau

1:38
Using MRD as an endpoint in clinical trials
Hervé Avet-Loiseau • 14 Sep 2019
14:15
Working towards a cure for multiple myeloma
Brian Walker et al. • 27 Jan 2017
11:23
Challenges and future perspectives for minimal residual disease (MRD) in multiple myeloma
Bruno Paiva et al. • 27 Jan 2017
3:22
The main prognostic factors and why minimal residual disease is becoming crucial in multiple myeloma
Hervé Avet-Loiseau • 30 Apr 2016

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals